HEREHilton Head Island
Why It Matters. HERE!
Latest Italian Maker ERRECINQUE Plans $5M Bluffton, S.C. Facility
☁ 36°F Clear · Hilton Head IslandFORECAST
HILTON HEAD ISLAND, SC · LOWCOUNTRY / BEAUFORT COUNTY EDITION · MONDAY, NOVEMBER 16, 2026
HERE City Network
Business

J&J in Talks to Buy Eye-Drug Maker Ollin for Up to $3.4 Billion

Published November 16, 2026 at 5:55 am | By Merger Monday, Staff Reporter

J&J Ollin Biosciences acquisition talks: J&J in Talks to Buy Eye-Drug Maker Ollin for Up to $3.4 Billion

Johnson & Johnson is in advanced talks to buy Ollin Biosciences, a privately held developer of eye-disease drugs, for as much as $3.4 billion, people familiar with the matter said, a move that would push the health-care giant deeper into retinal medicine.

Under the terms being discussed, J&J would pay Ollin investors about $2.2 billion in cash upfront and up to $1.2 billion more tied to development milestones, the people said. An agreement could be announced as soon as Monday, though the negotiations could still fall apart. A British business newspaper first reported the talks Sunday. J&J and Ollin did not comment.

HERE CITY BUSINESS DIRECTORYOwn a business in Hilton Head Island? Get listed HERE.Free basic listing. Premium features available.
ADD YOUR BUSINESS →

Going after the retina

Ollin, backed by ARCH Venture Partners and Mubadala Capital, is developing OLN324, an antibody designed to block two proteins, VEGF and Ang2, that drive abnormal blood vessel growth and leakage in the eye. The company has said it planned to begin late-stage trials in diabetic macular edema and wet age-related macular degeneration in the second half of 2026. It raised $330 million in June to pay for those studies.

Its pipeline also includes OLN102, a bispecific antibody targeting two receptors involved in thyroid eye disease and Graves disease.

The retinal market is dominated by injected drugs such as Regeneron and Bayer products and Roche, whose Vabysmo already hits the same two targets. J&J sells contact lenses and surgical vision equipment but has little presence in prescription retinal drugs, so a deal would give it a late-stage entry rather than starting from scratch.

A record year for biotech buyouts

The talks come in a record year for biotech takeovers. Investment bank Stifel has counted 46 acquisitions of biotech companies valued at more than $1 billion so far this year, above the previous annual high of 35. Recent examples include AstraZeneca and its roughly $10 billion offer for Rhythm Pharmaceuticals and argenx agreeing to buy Unnatural Products for up to $1.15 billion.

The structure under discussion, with a large slice of value held back for milestones, has become standard for drugs that have not yet finished pivotal trials. It lets the buyer cap what it pays if the science disappoints while giving venture backers a quick return on a company that has not had to test the public markets.

SPONSOR | Your Business Here — Be the brand Hilton Head Island's Business community sees first every morning. Exclusive top-of-section placement, Monday–Friday.
SPONSOR $199/MO →

Section: More Hilton Head Island SC business news

Hilton Head Island business profiles

Filed under: Hilton Head Island SC Business News

Merger Monday
HERE Hilton Head · BUSINESS

Merger is a staff reporter for HERE Hilton Head covering local news, community stories, and developments across Beaufort County. Merger is committed to accurate, community-first journalism.

Contact Merger
HEREmention Get Your Business Found in AI BE THE ANSWER. When customers ask ChatGPT, Perplexity, or Google AI who to hire — your name comes up. Learn More

BUSINESS NEWS NEAR HILTON HEAD ISLAND SC

Business coverage from the 10 closest HERE cities.